Every 8-K that BioAge Labs, Inc. (BIOA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 8-K covers material events a company has to report between its quarterly reports, so if you follow BIOA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full BIOA filings page.
BioAge Labs, Inc. reported collaboration revenue of $2.4 million for the quarter ended June 30, 2026, unchanged from the prior-year period. Research and development expenses rose to $24.4 million, mainly from higher spending on lead NLRP3 inhibitor BGE-102, including the Phase 2 QUELL-CV trial and planned QUELL-DME study, while general and administrative expenses were $7.4 million. Net loss was $26.1 million, or $0.58 per share.
As of June 30, 2026, BioAge held approximately $381.3 million in cash, cash equivalents and marketable securities and expects this to fund operations and capital expenses through 2029. The company dosed the first participant in QUELL-CV, a Phase 2 proof-of-concept trial of BGE-102 in about 160 adults with obesity and elevated inflammation, and plans to start QUELL-DME, a Phase 1b/2a trial in diabetic macular edema, in mid-2026. BioAge also continues its APJ agonist obesity program and multi-year discovery collaborations with Novartis and Lilly ExploR&D.
BioAge Labs, Inc. reported the results of its 2026 Annual Meeting of Stockholders held on June 10, 2026. Stockholders elected three Class II directors — Patrick Enright, James I. Healy, and Rekha Hemrajani — each to serve a three-year term expiring at the 2029 annual meeting.
Enright received 30,075,928 shares voted for and 1,184,271 withheld, Healy received 25,499,205 for and 5,760,994 withheld, and Hemrajani received 27,826,781 for and 3,433,418 withheld, with 5,327,405 broker non-votes for each nominee. Stockholders also ratified KPMG LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 36,561,171 shares for, 1,305 against, and 25,128 abstaining.
BioAge Labs, Inc. reported first quarter 2026 results, highlighting pipeline progress and a larger operating loss as it invests in development. Collaboration revenue was $2.8 million versus $1.5 million a year earlier, driven by higher work under its Novartis collaboration.
Research and development expenses rose to $20.4 million and general and administrative expenses to $7.7 million, leading to a net loss of $22.3 million or $0.52 per share, compared with a $12.9 million loss in 2025. The company closed an upsized follow-on public offering with gross proceeds of about $132.3 million and ended March 31, 2026 with $384.9 million in cash, cash equivalents and marketable securities, which it expects to fund operations through 2029.
BioAge reported positive Phase 1 data for its oral NLRP3 inhibitor BGE-102, showing median 86% reductions in hsCRP at 60 mg and 120 mg once-daily doses and a favorable safety profile. It plans to start a Phase 2 cardiovascular risk study and a Phase 1b/2a diabetic macular edema trial for BGE-102 in mid-2026, while advancing APJ agonist programs toward an initial IND filing by year-end 2026.
BioAge Labs reported full-year 2025 results showing its transition into a later-stage clinical company. Collaboration revenue reached $9.0 million, driven by work under a multi-year Novartis research collaboration, while research and development expenses rose to $73.9 million and general and administrative expenses to $27.8 million as the pipeline and public-company infrastructure expanded. Net loss was $80.6 million, or $2.24 per share, compared with a $71.1 million loss in 2024. The company ended 2025 with $285.1 million in cash, cash equivalents, and marketable securities and estimates this will fund operations through 2029. Clinically, lead NLRP3 inhibitor BGE-102 delivered positive interim Phase 1 data, including an 86% median hsCRP reduction at 120 mg once daily and strong IL‑1β suppression, supporting Phase 2a cardiovascular risk and ophthalmology trials beginning in 2026. BioAge also advanced its APJ agonist programs toward an initial IND by late 2026 and strengthened its balance sheet via a $132.3 million upsized follow-on equity offering.
BioAge Labs, Inc. entered into an underwriting agreement to sell 5,897,435 shares of common stock at $19.50 per share in a public offering, with underwriters holding a 30-day option to buy up to an additional 884,615 shares. The transaction is being conducted under the company’s effective shelf registration statement on Form S-3. BioAge estimates net proceeds of about $107.6 million after underwriting discounts and expenses, assuming the option is not exercised.
The company plans to use these funds, together with existing cash, cash equivalents and marketable securities, to support research, clinical and process development and manufacturing for its product candidates, including BGE-102 and its NLRP3 and APJ programs, as well as for working capital, capital expenditures, reduction of indebtedness and other general corporate purposes. Closing of the offering is expected on January 23, 2026, subject to customary conditions.
BioAge Labs, Inc. filed a current report describing an indication expansion for its oral NLRP3 inhibitor BGE-102 and outlining upcoming clinical milestones. The company plans to start a Phase 1b/2a proof-of-concept trial in patients with diabetic macular edema (DME) in mid-2026.
In a preclinical DME model, oral BGE-102 showed dose-dependent preservation of retinal vascular integrity, with near-complete protection from vascular leakage and up to 90% preservation of microvascular integrity. BGE-102 has shown favorable tolerability to date in an ongoing Phase 1 trial, alongside robust reductions in inflammatory biomarkers such as hsCRP, IL-6, and IL-1β.
The development plan includes completing the Phase 1 trial with full data in the first half of 2026, starting a Phase 2a proof-of-concept trial in obesity with cardiovascular risk factors in the first half of 2026, initiating the DME Phase 1b/2a trial in mid-2026, and targeting data readouts for the cardiovascular trial in the second half of 2026 and for the DME trial in mid-2027.
BioAge Labs, Inc. reported additional positive interim Phase 1 results for BGE-102, a novel brain-penetrant NLRP3 inhibitor being tested in people with obesity and elevated cardiovascular risk. In the first multiple ascending dose cohort, participants receiving 120 mg once daily showed rapid and marked anti-inflammatory effects, including an 86% reduction in hsCRP at Day 14, with 93% of participants reaching normalized hsCRP levels below 2 mg/L.
BGE-102 also produced significant reductions in IL-6 and fibrinogen, two biomarkers linked to systemic inflammation and cardiovascular events, and was described as well tolerated with a favorable safety profile. The company highlighted a newly issued patent covering additional composition of matter and a novel NLRP3 binding site. Planned milestones include completing the Phase 1 trial and initiating a Phase 2a proof-of-concept study in the first half of 2026, followed by Phase 2a data in the second half of 2026.
BioAge Labs, Inc. furnished an 8‑K announcing it issued a press release with financial results for the third quarter ended September 30, 2025. The disclosure is under Item 2.02 (Results of Operations and Financial Condition) and includes Exhibit 99.1 containing the press release. The company notes the information is furnished and not deemed filed under the Exchange Act or the Securities Act. BIOA common stock trades on the Nasdaq Global Select Market.